350 related articles for article (PubMed ID: 17604541)
1. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.
Cosma A; Nagaraj R; Staib C; Diemer C; Wopfner F; Schätzl H; Busch DH; Sutter G; Goebel FD; Erfle V
AIDS Res Hum Retroviruses; 2007 Jun; 23(6):782-93. PubMed ID: 17604541
[TBL] [Abstract][Full Text] [Related]
2. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.
Greenberg RN; Overton ET; Haas DW; Frank I; Goldman M; von Krempelhuber A; Virgin G; Bädeker N; Vollmar J; Chaplin P
J Infect Dis; 2013 Mar; 207(5):749-58. PubMed ID: 23225902
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
4. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
Parrino J; McCurdy LH; Larkin BD; Gordon IJ; Rucker SE; Enama ME; Koup RA; Roederer M; Bailer RT; Moodie Z; Gu L; Yan L; Graham BS;
Vaccine; 2007 Feb; 25(8):1513-25. PubMed ID: 17126963
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
[TBL] [Abstract][Full Text] [Related]
6. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis.
von Sonnenburg F; Perona P; Darsow U; Ring J; von Krempelhuber A; Vollmar J; Roesch S; Baedeker N; Kollaritsch H; Chaplin P
Vaccine; 2014 Sep; 32(43):5696-702. PubMed ID: 25149431
[TBL] [Abstract][Full Text] [Related]
8. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Wyatt LS; Earl PL; Eller LA; Moss B
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
[TBL] [Abstract][Full Text] [Related]
9. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge.
Edghill-Smith Y; Bray M; Whitehouse CA; Miller D; Mucker E; Manischewitz J; King LR; Robert-Guroff M; Hryniewicz A; Venzon D; Meseda C; Weir J; Nalca A; Livingston V; Wells J; Lewis MG; Huggins J; Zwiers SH; Golding H; Franchini G
J Infect Dis; 2005 Feb; 191(3):372-81. PubMed ID: 15633096
[TBL] [Abstract][Full Text] [Related]
10. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
McCurdy LH; Rutigliano JA; Johnson TR; Chen M; Graham BS
J Virol; 2004 Nov; 78(22):12471-9. PubMed ID: 15507634
[TBL] [Abstract][Full Text] [Related]
11. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.
Perera LP; Waldmann TA; Mosca JD; Baldwin N; Berzofsky JA; Oh S
J Virol; 2007 Aug; 81(16):8774-83. PubMed ID: 17553867
[TBL] [Abstract][Full Text] [Related]
12. Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin.
Jones-Trower A; Garcia A; Meseda CA; He Y; Weiss C; Kumar A; Weir JP; Merchlinsky M
Virology; 2005 Dec; 343(1):128-40. PubMed ID: 16165184
[TBL] [Abstract][Full Text] [Related]
13. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.
Stittelaar KJ; van Amerongen G; Kondova I; Kuiken T; van Lavieren RF; Pistoor FH; Niesters HG; van Doornum G; van der Zeijst BA; Mateo L; Chaplin PJ; Osterhaus AD
J Virol; 2005 Jun; 79(12):7845-51. PubMed ID: 15919938
[TBL] [Abstract][Full Text] [Related]
14. Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
McCurdy LH; Larkin BD; Martin JE; Graham BS
Clin Infect Dis; 2004 Jun; 38(12):1749-53. PubMed ID: 15227622
[TBL] [Abstract][Full Text] [Related]
15. Smallpox vaccine, ACAM2000: Sites and duration of viral shedding and effect of povidone iodine on scarification site shedding and immune response.
Pittman PR; Garman PM; Kim SH; Schmader TJ; Nieding WJ; Pike JG; Knight R; Johnston SC; Huggins JW; Kortepeter MG; Korman L; Ranadive M; Quinn X; Meyers MS
Vaccine; 2015 Jun; 33(26):2990-6. PubMed ID: 25930115
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of human immunological responses to vaccinia virus.
Harrop R; Ryan MG; Golding H; Redchenko I; Carroll MW
Methods Mol Biol; 2004; 269():243-66. PubMed ID: 15114020
[TBL] [Abstract][Full Text] [Related]
17. Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection.
Knitlova J; Hajkova V; Voska L; Elsterova J; Obrova B; Melkova Z
PLoS One; 2014; 9(12):e114374. PubMed ID: 25486419
[TBL] [Abstract][Full Text] [Related]
18. E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.
Volz A; Jany S; Freudenstein A; Lantermann M; Ludwig H; Sutter G
Viruses; 2018 Jan; 10(1):. PubMed ID: 29300297
[TBL] [Abstract][Full Text] [Related]
19. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
[TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.
Overton ET; Stapleton J; Frank I; Hassler S; Goepfert PA; Barker D; Wagner E; von Krempelhuber A; Virgin G; Meyer TP; Müller J; Bädeker N; Grünert R; Young P; Rösch S; Maclennan J; Arndtz-Wiedemann N; Chaplin P
Open Forum Infect Dis; 2015 Apr; 2(2):ofv040. PubMed ID: 26380340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]